Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Compound medicament for treating T-cell acute lymphoblastic leukemia (T-ALL)

A technology of lymphocytes and leukemia, applied in the field of medicine, can solve the problems of unsatisfactory killing of leukemia cells, large side effects of leukemia patients, etc., achieve good application value, better therapeutic effect, and inhibit T-ALL cancer cells Effect

Inactive Publication Date: 2016-08-31
WUHAN UNIV OF TECH
View PDF3 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In the prior art, the side effects of chemotherapy on leukemia patients are relatively large, and the killing of leukemia cells is not satisfactory

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound medicament for treating T-cell acute lymphoblastic leukemia (T-ALL)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Embodiment 1: Compound drug for the treatment of acute T lymphocytic leukemia

[0032] The compound medicine is made from the following raw materials in parts by weight:

[0033] Angelica polysaccharide 30 parts, astragalosides 25 parts, ligustrazine 10 parts, American ginseng total saponins 15 parts.

Embodiment 2

[0034] Embodiment 2: Compound drug for the treatment of acute T lymphocytic leukemia

[0035] The compound medicine is made from the following raw materials in parts by weight:

[0036] Angelica polysaccharide 20 parts, astragalosides 20 parts, ligustrazine 10 parts, American ginseng total saponins 15 parts.

Embodiment 3

[0037] Embodiment 3: Compound drug for the treatment of acute T lymphocytic leukemia

[0038] The compound medicine is made from the following raw materials in parts by weight:

[0039] Angelica polysaccharide 20 parts, astragalosides 15 parts, ligustrazine 5 parts, American ginseng total saponins 10 parts.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a compound medicament for treating T-cell acute lymphoblastic leukemia (T-ALL). The compound medicament is prepared from the following raw materials in parts by weight: 10-30 parts of angelica polysaccharides, 10-25 parts of astragnalosides, 5-10 parts of ligustrazine and 5-15 parts of total American ginseng saponins. The traditional Chinese medicine extract compound medicament has obviously less adverse response and side effects than Western medicine, and is comprehensive in effect and better in treatment effect; compared with a chemical treatment method, the compound medicament significantly improves the compliance of patients on medicines, and improves the living quality of patients; the compound medicament can obviously improve the inhibiting effect on leukemia, and has selectivity on leukemia cells; the compound medicament can effectively inhibit T-ALL cancer cells, and has good application value for treating leukemia.

Description

technical field [0001] The invention belongs to the field of medicine, in particular to a compound medicine for treating acute T lymphocytic leukemia. Background technique [0002] Leukemia is a malignant tumor of the hematopoietic system. Leukemia has a rapid onset, dangerous condition, and complex etiology, which poses a huge threat to human life. Over the years, scientific researchers around the world have continuously explored the pathogenic mechanism of leukemia, and gradually gained some consensus: the human body regulates hematopoiesis in an extremely fine manner, mainly including the interaction of genes on hematopoietic stem cells, the influence of normal hematopoietic microenvironment, positive and negative Induction of hematopoietic regulatory factors, etc. The coordinated interaction of genes on hematopoietic stem cells makes hematopoietic progenitor cells moderately self-renew, differentiate and mature or undergo apoptosis, so as to ensure that the number of no...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/481A61P35/02A61K31/4965A61K36/258A61K31/715A61K36/232
CPCA61K31/4965A61K31/715A61K36/232A61K36/258A61K36/481A61K2300/00
Inventor 楼一层王子望刘萌萌朱影张浩龙添刘娟陈相东
Owner WUHAN UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com